Spots Global Cancer Trial Database for cabozantinib
Every month we try and update this database with for cabozantinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | NCT04211337 | Medullary Thyro... | Selpercatinib Cabozantinib Vandetanib | 12 Years - | Eli Lilly and Company | |
| Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors | NCT04767906 | Hepatocellular ... | Cabozantinib | 18 Years - | University of Leipzig | |
| Cabozantinib for Advanced Urothelial Cancer | NCT01688999 | Urothelial Carc... Urethral Neopla... Urinary Bladder... Kidney Neoplasm... | Cabozantinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | NCT05048901 | Neuroendocrine ... | Cabozantinib Lanreotide | 20 Years - | National Health Research Institutes, Taiwan | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Cabozantinib in Advanced Salivary Gland Cancer Patients | NCT03729297 | Salivary Gland ... | Cabozantinib | 18 Years - | Radboud University Medical Center | |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | NCT02795156 | Non-small Cell ... Urothelial Carc... Gastrointestina... Upper Aerodiges... | Afatinib Regorafenib Cabozantinib | 18 Years - | SCRI Development Innovations, LLC | |
| Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | NCT02132598 | Non Small Cell ... Metastases to t... | cabozantinib | 18 Years - | University of Pittsburgh | |
| Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | NCT04471428 | Carcinoma, Non-... | Cabozantinib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma | NCT05100082 | Hepatocellular ... | Cabozantinib | - | Takeda | |
| Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | NCT03542877 | Colorectal Canc... | Oral Tablet: Ca... | 18 Years - 99 Years | University of Colorado, Denver | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | NCT05048901 | Neuroendocrine ... | Cabozantinib Lanreotide | 20 Years - | National Health Research Institutes, Taiwan | |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | NCT05836571 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Undi... | Biopsy Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | NCT04338269 | Carcinoma, Rena... | Atezolizumab Cabozantinib | 18 Years - | Hoffmann-La Roche | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | NCT03793166 | Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ... | Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | NCT02036476 | Merkel Cell Car... Skin Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05613894 | Metastatic Cast... | Cabozantinib | 18 Years - | University of Utah | |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | NCT04963283 | Colorectal Aden... Colon Cancer Colon Adenocarc... Rectum Cancer Rectal Cancer Rectal Adenocar... Colorectal Canc... | Cabozantinib Nivolumab | 18 Years - | University of Colorado, Denver | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | NCT04497038 | Advanced Adult ... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | NCT01582295 | Multiple Myelom... | Cabozantinib | 18 Years - | Massachusetts General Hospital | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| Cabozantinib in Advanced Salivary Gland Cancer Patients | NCT03729297 | Salivary Gland ... | Cabozantinib | 18 Years - | Radboud University Medical Center | |
| Cabozantinib for Patients With Recurrent or Progressive Meningioma | NCT05425004 | Meningioma | Cabozantinib | 18 Years - | Baptist Health South Florida | |
| Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | NCT05200143 | Refractory Cuta... | Ipilimumab Nivolumab Cabozantinib | 18 Years - | Providence Health & Services | |
| Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | NCT04149275 | Carcinosarcoma ... Carcinosarcoma ... Carcinosarcoma ... | Cabozantinib Ipilimumab Nivolumab | 18 Years - | University of Alabama at Birmingham | |
| A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | NCT04876456 | Germ Cell Tumor Seminoma Non-seminomatou... Ovarian Germ Ce... | Cabozantinib | - | Indiana University | |
| Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | NCT04471428 | Carcinoma, Non-... | Cabozantinib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone | NCT01428219 | Prostate Cancer... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib | NCT05265988 | Carcinoma Prost... | Cabozantinib | - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. | NCT04066595 | Urothelial Carc... | Cabozantinib | 18 Years - | Johannes Gutenberg University Mainz | |
| A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | NCT02041260 | Differentiated ... Poorly Differen... | Cabozantinib | 18 Years - | Thomas Jefferson University | |
| Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT04631744 | Prostate Cancer | Cabozantinib | 18 Years - 99 Years | Weill Medical College of Cornell University | |
| Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma | NCT04416646 | Renal Cell Carc... | Cabozantinib | 70 Years - | Istituto Oncologico Veneto IRCCS | |
| Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma | NCT04416646 | Renal Cell Carc... | Cabozantinib | 70 Years - | Istituto Oncologico Veneto IRCCS | |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | NCT04540705 | Renal Cell Carc... | Nivolumab Axitinib Cabozantinib | 18 Years - | Bristol-Myers Squibb | |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | NCT05263050 | Metastatic Rena... Clear-cell Meta... | Cabozantinib Nivolumab | 18 Years - | Fox Chase Cancer Center | |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | NCT04400474 | Neuroendocrine ... Anaplastic Thyr... Adenocarcinoma Pheochromocytom... Paraganglioma | Cabozantinib 40... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | NCT03635892 | Advanced or Met... Unclassified Re... Papillary Renal... Fumarate Hydrat... Succinate Dehyd... Collecting Duct... Chromophobe Ren... | cabozantinib nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) | NCT03963206 | Hepatocellular ... | Cabozantinib gr... | 18 Years - | Hospices Civils de Lyon | |
| Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | NCT04022343 | Clear Cell Rena... Renal Cell Carc... Stage III Renal... | Cabozantinib | 18 Years - | Emory University | |
| Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | NCT06377722 | Renal Cell Carc... Renal Cell Carc... Renal Cell Carc... | Cabozantinib | 18 Years - | Fundacion Oncosur | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function | NCT04454762 | Hepatocellular ... | Cabozantinib | 18 Years - | Johannes Gutenberg University Mainz | |
| Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) | NCT05289856 | Cancer | combination of ... | 18 Years - | Johannes Gutenberg University Mainz | |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | NCT04413123 | Papillary Renal... Unclassified Re... Translocation R... Chromophobe Ren... Collecting Duct... Renal Cell Carc... Unresectable Ad... Metastatic Ncc ... | Cabozantinib Nivolumab Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | NCT01834651 | Prostate Cancer | Cabozantinib | 18 Years - | Cedars-Sinai Medical Center | |
| A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | NCT05039736 | Hepatocellular ... Liver Cancer | Cabozantinib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | NCT04413123 | Papillary Renal... Unclassified Re... Translocation R... Chromophobe Ren... Collecting Duct... Renal Cell Carc... Unresectable Ad... Metastatic Ncc ... | Cabozantinib Nivolumab Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| Cabozantinib for Patients With Recurrent or Progressive Meningioma | NCT05425004 | Meningioma | Cabozantinib | 18 Years - | Baptist Health South Florida | |
| Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT05007613 | Esophageal Canc... Metastatic Canc... Squamous Cell C... | Cabozantinib 40... Atezolizumab In... | 20 Years - | National Taiwan University Hospital | |
| Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma | NCT03534804 | Metastatic Urot... Bladder Cancer | Cabozantinib Pembrolizumab | 18 Years - | University of Utah | |
| Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | NCT03149822 | Metastatic Rena... | Cabozantinib Pembrolizumab | 18 Years - 100 Years | University of Colorado, Denver | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | NCT02885324 | Glioblastoma Mu... Anaplastic Astr... Malignant Brain... High Grade Glio... | Cabozantinib | 2 Years - 21 Years | Indiana University | |
| Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | NCT03149822 | Metastatic Rena... | Cabozantinib Pembrolizumab | 18 Years - 100 Years | University of Colorado, Denver | |
| Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT04631744 | Prostate Cancer | Cabozantinib | 18 Years - 99 Years | Weill Medical College of Cornell University | |
| XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937 | Prostate Cancer | Cabozantinib Abiraterone | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). | NCT04760288 | Medullary Thyro... | Pralsetinib Cabozantinib Vandetanib | 12 Years - | Hoffmann-La Roche | |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| Cabozantinib and Nivolumab for Carcinoid Tumors | NCT04197310 | Carcinoid Tumor Carcinoid Tumor... Neuroendocrine ... | Nivolumab Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | NCT05188118 | Renal Cell Carc... | Cabozantinib Ipilimumab Nivolumab Lenvatinib Everolimus | 18 Years - 99 Years | Icahn School of Medicine at Mount Sinai | |
| A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | NCT05048212 | Brain Metastase... Renal Cell Carc... | Nivolumab Ipilimumab Cabozantinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | NCT04338269 | Carcinoma, Rena... | Atezolizumab Cabozantinib | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | NCT05039281 | Recurrent Gliob... Recurrent Glios... | Atezolizumab Cabozantinib | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | NCT05263050 | Metastatic Rena... Clear-cell Meta... | Cabozantinib Nivolumab | 18 Years - | Fox Chase Cancer Center | |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | NCT01466036 | Carcinoid Tumor Pancreatic Neur... | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | NCT04497038 | Advanced Adult ... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | NCT06377722 | Renal Cell Carc... Renal Cell Carc... Renal Cell Carc... | Cabozantinib | 18 Years - | Fundacion Oncosur | |
| Ph II CABOGIST in GIST | NCT02216578 | Metastatic Gast... | cabozantinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Spanish Real-World Evidence Cabozantinib | NCT04510688 | Renal Cell Carc... | Cabozantinib | 18 Years - | Spanish Oncology Genito-Urinary Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
